Joshua T. Brumm - Oct 7, 2022 Form 4 Insider Report for Dyne Therapeutics, Inc. (DYN)

Role
Chief Executive Officer and President, Director
Signature
/s/ Richard Scalzo, Attorney-in-Fact
Stock symbol
DYN
Transactions as of
Oct 7, 2022
Transactions value $
-$2,413,222
Form type
4
Date filed
10/11/2022, 09:00 AM
Previous filing
Sep 21, 2022
Next filing
Dec 13, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DYN Common Stock Options Exercise $14.6K +14.2K +6.94% $1.03* 219K Oct 7, 2022 Direct
transaction DYN Common Stock Sale -$190K -14.2K -6.49% $13.37 205K Oct 7, 2022 Direct F1
transaction DYN Common Stock Options Exercise $202K +196K +95.69% $1.03* 400K Oct 10, 2022 Direct
transaction DYN Common Stock Sale -$2.44M -196K -48.9% $12.46 205K Oct 10, 2022 Direct F2
transaction DYN Common Stock Gift $0 -13K -6.35% $0.00 192K Oct 10, 2022 Direct F3
transaction DYN Common Stock Gift $0 -2.5K -1.3% $0.00 189K Oct 10, 2022 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DYN Stock Option (right to buy) Options Exercise $0 -14.2K -2.55% $0.00 544K Oct 7, 2022 Common Stock 14.2K $1.03 Direct F4
transaction DYN Stock Option (right to buy) Options Exercise $0 -196K -36.02% $0.00 348K Oct 10, 2022 Common Stock 196K $1.03 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $12.70 to $13.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) of this Form 4.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $12.30 to $12.91, inclusive.
F3 This transaction was a charitable donation to a third party effective October 10, 2022 in which no value was received in return.
F4 The option was granted on January 6, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on October 12, 2020 and the remaining shares vesting in equal quarterly installments thereafter.

Remarks:

Chief Executive Officer and President